Controlled backfill in oncology dose-finding trials.
Sign Up to like & getrecommendations! Published in 2021 at "Contemporary clinical trials"
DOI: 10.1016/j.cct.2021.106605
Abstract: The use of backfill in early phase dose-finding trials is a relatively recent practice. It consists of assigning patients to dose levels below the level where the study is at. The main reason for backfilling… read more here.
Keywords: dose finding; dose level; finding trials; patients dose ... See more keywords
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.09.131
Abstract: Introduction: This phase I trial was conducted to determine the safety, maximum tolerated dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients with advanced NSCLC. Methods: Patients with NSCLC and an… read more here.
Keywords: phase; dose level; erlotinib patients; patients advanced ... See more keywords
P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC: Topic: EGFR RES
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.11.1787
Abstract: Results: At the data cut-off (Aug 1, 2016), 33 patients were enrolled at five capmatinib BID/EGF816 QD mg dose levels (200/50 [n1⁄44]; 200/100 [n1⁄45]; 400/75 [n1⁄43]; 400/100 [n1⁄416]; 400/150 mg [n1⁄45]); 18/33 (55%) patients discontinued… read more here.
Keywords: 400 150; egfr; dose level; 400 100 ... See more keywords
Dose-Optimized Computed Tomography for Screening and Follow-Up of Solid Pulmonary Nodules in Obesity: A Phantom Study.
Sign Up to like & getrecommendations! Published in 2017 at "Current problems in diagnostic radiology"
DOI: 10.1067/j.cpradiol.2016.07.005
Abstract: To determine the lowest CT radiation dose-level at maintained image-quality and high sensitivity for detection of pulmonary-nodules in obesity. Single-energy CT with tin-filtration was performed in a chest-phantom with solid pulmonary-nodules simulating over-weight and obesity.… read more here.
Keywords: phantom; image quality; solid pulmonary; dose level ... See more keywords
ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.104
Abstract: Therapies targeting multiple survival pathways are desirable for high-grade gliomas. TG02 (Zotiraciclib), a CDK9 inhibitor, regulates transcription and metabolism of tumor cells and synergizes with temozolomide. A phase I/II trial was launched to test the… read more here.
Keywords: dose level; recurrent high; tg02; high grade ... See more keywords
ACTR-63. PHASE I DOSE ESCALATION STUDY OF PROCASPASE ACTIVATING COMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE IN PATIENTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.105
Abstract: Procaspase activating compound -1 (PAC-1) is a small molecule that catalyzes conversion of procaspase-3 to caspase-3 which induces apoptosis in cancer cells. Glioblastoma (GBM) is among the tumors with high concentrations of procaspase-3 and low… read more here.
Keywords: procaspase activating; dose level; compound pac; level ... See more keywords
Abstract CT133: Results of phase I study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple negative breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2021-ct133
Abstract: Background: A previous neoadjuvant study in patients with triple negative breast cancer (TNBC) demonstrated that low tumor infiltrating lymphocytes (TILs) after neoadjuvant chemotherapy is associated with a poor outcome. Activation of RAS/MAPK pathway has been… read more here.
Keywords: binimetinib; dose level; cancer; level ... See more keywords
Abstract CT194: ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct194
Abstract: Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitization. ETCTN… read more here.
Keywords: lutetium 177; dotatate; 177 dotatate; triapine ... See more keywords
Comparison of design methods for a safety run-in phase of a phase II clinical trial
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Trials"
DOI: 10.1177/17407745221140913
Abstract: Background/Aims: In pediatric oncology, a Phase II trial often utilizes a safety run-in phase followed by an efficacy phase that enrolls at the dose level selected based on the safety run-in. Different from a Phase… read more here.
Keywords: safety; design; safety run; phase ... See more keywords
Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Anticancer research"
DOI: 10.21873/anticanres.11620
Abstract: BACKGROUND/AIM Prognoses of patients receiving radio-chemotherapy with 5-fluorouracil (5-FU) and cisplatin for unresectable esophageal cancer may be improved with the addition of cetuximab. This phase I study aimed to define the maximum tolerated dose of… read more here.
Keywords: dose level; cisplatin; radio chemotherapy; cetuximab ... See more keywords
Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.3324/haematol.2019.225375
Abstract: Approval of bortezomib revolutionized the treatment of multiple myeloma (MM). Since then, second-generation proteasome inhibitors (PI) (carfilzomib and oral ixazomib) have been developed and approved. Panobinostat, a pan-deacetylase inhibitor (HDACi) has been approved in combination… read more here.
Keywords: phase; dose level; dexamethasone; carfilzomib ... See more keywords